心功能不全患者血浆BNP、NT—proBNP检测分析

Cardiac dysfunction patients plasma BNP, NT-proBNP testing analysis

目的探讨血浆脑钠肽（BNP）和氨基末端B型尿钠肽前体（NT-proBNP）变化与心功能不全患者血管病变的关系。方法108例心功能不全患者发病后2周内采静脉血分离血清，28例非心脏病患者作为正常对照组，用电化学发光法测定BNP和NT-proBNP。结果对照组、心功能Ⅰ级组、Ⅱ级组、Ⅲ级组、Ⅳ级组血浆BNP水平分别是（51．34±11．27）、（155．06±39．12）、（247．05±68．34）、（513．17±127．88）（612．34±155．87）。NT—proBNP（μg／L）水平分别是（25．78±14．49）、（177．86±143．65）、（299．81±166．09）、（608．17±123．14）、（979．04±176．45），组间比较差异均有统计学意义（P〈0．01）。结论血浆BNP水平升高与冠脉病变的严重程度有关，NT-proBNP可用于早期评价心脏收缩功能不全，早期评价舒张功能不全和心室壁节段运动协调性。

Objective To explore the plasma BNP （BNP） and amino-terminal type B urinary sodium peptide precursor （NT-proBNP） change and cardiac function in patients with vascular lesions of the relationship. Methods 108 cases of patients with cardiac insufficiency 2 weeks after venous serum in separation, 28 eases of patients with heart dis- ease as a normal control group, the chemical luminescence method to determine the BNP and NT-proBNP. Results The control group, and cardiac function Ⅰ level group, Ⅱ level group, Ⅲ level group, Ⅳ plasma BNP levels level group were （51.34±11.27, 155.06±39.12, 247.05±68.34, 513.17±127.88 （612.34± 155.87）. NT-proBNP （μ g/L） levels were 125.78±14. 49, 177.86 ± 143.65, 299.81 ±166.09, 608. 17 ± 123.14, 979.04 ± 176.45 ）, comparative differences between groups are statistically significant （P〈0.01）. Conclusion Plasma BNP levels rise and the severity of the coronary lesions, NT-proBNP can be used to evaluate the heart to contract early function is not complete, early evaluation diastolic dysfunction and ventricular segmental wall motion coordination.